Table 4 Primary and secondary outcomes in the studied RPGN patients
Variables | Total patients n = 101 | Type I RPGN n = 20 | Type II RPGN n = 48 | Type III RPGN n = 33 |
|---|---|---|---|---|
Primary outcomes | ||||
 ESRD | 60 (59.4%) | 12 (60%) | 30 (62.5%) | 18 (54.5%) |
 Death | 32 (31.7%) | 8 (40%) | 12 (25%) | 12 (36.4%) |
 Partial remission | 30 (29.7%) | 8 (40%) | 12 (25%) | 10 (30.3%) |
 Complete remission | 11 (10.9%) | 0 (0%) | 6 (12.5%) | 5 (15.2%) |
Secondary outcomes | ||||
 Infections | 46 (45.5%) | 10 (50%) | 22 (45.8%) | 14 (42.4%) |
 Heart failure | 40 (39.6%) | 10 (50%) | 14 (29.2%) | 16 (48.5%) |
 Respiratory failure | 29 (28.7%) | 6 (30%) | 14 (29.2%) | 9 (27.3%) |
 Diabetes mellitus | 23 (22.8%) | 6 (30%) | 10 (20.8%) | 7 (21.2%) |